Introduction
About 10-20 % of patients with gastric cancer develop peritoneal dissemination. Furthermore, 60 % of patients with T3 or T4 tumor develop peritoneal recurrence after curative resection [1] . Peritoneal dissemination is considered an independent factor for poor prognosis [2] . While many treatment strategies have been developed to manage peritoneal carcinomatosis (PC) derived from gastric cancer, the outcomes remain poor. A recent large-scale study of PC managed with cytoreductive surgery and perioperative intraperitoneal chemotherapy showed that the median overall survival (OS) of patients with PC derived from gastric cancer was only 7-15 months [3, 4] . Even with complete cytoreductive surgery, the 2-year survival rate of patients with, P3 grade PC derived from gastric cancer, classified by Japanese classification of gastric carcinoma, was only 2 % [5] .
Several clinical trials of newly developed chemotherapeutic drugs have been conducted. However, few studies have been performed in patients with gastric cancer with PC. Furthermore, it is difficult to include patients with no measurable disease in such clinical trials. In some phase 3 clinical trials, these patients comprised only 5-20 % of the overall patient population [6, 7] . Subgroup analysis suggested that patients without measurable disease had somewhat better survival than those with measurable disease, although the presence of PC was a poor prognostic factor [7] . Recently, the effect of systemic chemotherapy on colorectal cancer with PC was retrospectively analyzed. However, to our knowledge, no information on the effect of systemic chemotherapy on gastric cancer with PC is available at present [8] . In the present study, we characterized the outcomes of systemic chemotherapy and prognostic factors for patients with PC from gastric cancer, with a particular focus on patients without measurable disease.
Patients, materials, and methods

Patients and methods
After approval was obtained from the Institutional Review Board, patients diagnosed with recurrent or metastatic gastric cancer and treated at Seoul St. Mary's hospital between January 2003 and December 2010 were identified through the cancer registry. Among the patients with recurrent and metastatic gastric cancer, those who met the following criteria were included: (1) pathologically confirmed gastric adenocarcinoma; (2) PC diagnosed with abdominopelvic computed tomodensitometry (CT) scan or surgery; (3) no other distant metastasis, such as liver, lung, or bone; and no extraabdominal metastatic lymphadenopathy (LAP), such as supraclavicular LAP, diagnosed with abdominopelvic CT scan, whole-body bone scan, and/or positron emission tomography CT scan. (4) All patients had normal bone marrow, hepatic, and renal functions. (5) All patients received systemic chemotherapy. (6) Response assessment was performed every 2-3 cycles, based on the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.0 criteria, depending on the chemotherapeutic regimen. (7) Disease progression of evaluable disease (no measurable lesion) was assessed using RECIST criteria [9] .
The TNM classification of the American Joint Committee on Cancer staging version 6.0 was used. Clinical staging was applied in cases where pathologic staging was unavailable. A gastrointestinal radiologist (Y. R. Shin) retrospectively reviewed each initial CT scan for the presence of measurable disease, using RECIST version 1.0 criteria, and if the primary lesion included a measurable lesion, determined whether it satisfied the RECIST version 1.0 criteria [9] . Clinical characteristics of PC at the initial abdominopelvic CT scan, such as peritoneal thickening or enhancement, either smooth or nodular; small and large bowel involvement with wall thickening and bowel distension; involvement of the omentum, such as soft-tissue permeation of fat, enhancing nodules, or omental cake; and the presence of ascites were retrospectively reviewed and graded. We selected overall survival (OS) and progressionfree survival (PFS) as the main parameters of clinical outcome, because reports of the response rate (RR) were limited, owing to the difficulty of evaluating the response and the difficulty of assessing the RR. After the chemotherapy was completed, disease status was evaluated with abdominopelvic CT, every 3 months if patients were asymptomatic, or when they developed symptoms.
Statistical methods
The frequencies and descriptive statistics of demographic and clinical variables were determined. The v 2 test and Fisher's exact test were used for categorical variables and Student's t-test was used for continuous and ordinal variables, as appropriate. The OS time was calculated from the date of diagnosis to date of death or last known follow up. The PFS time was calculated from the date of diagnosis to the first documentation of disease recurrence or death or known follow up. The survival times were estimated using the Kaplan-Meier method, and the log-rank test was employed to compare survival curves. Univariate and multivariate predictors of OS and PFS were determined using the Cox proportional hazards model. Rate ratios and their 95 % confidence intervals (CIs) were calculated. The SPSS program for Windows (ver. 15.0; SPSS, Chicago, IL, USA) was used for analysis.
Results
Patient characteristics
Overall, 211 gastric adenocarcinoma patients with PC were identified from the cancer registry. Median follow-up duration was 15.0 months (range 1. (Table 2) . At the time of diagnosis, 2 patients had a total hysterectomy with bilateral salpingooophorectomy and 1 patient had an oophorectomy only. In terms of clinical characteristics, PC was classified into three grades. Grade 0 was defined as peritoneal seeding detected during operation with no evidence of PC in the preoperative evaluation, and grade 1 was defined as peritoneal seeding or ascites detected from an abdominopelvic CT scan; however, no bowel involvement or need for paracentesis was recorded. Grade 2 was defined as bowel wall involvement (gastric, small bowel, and large bowel wall) or a large amount of ascites requiring paracentesis. According to this carcinomatosis grading system, 39 (28.5 %), 48 (35.0 %), and 50 (36.5 %) of the 137 patients without measurable disease and 9 (12.2 %), 40 (54.1 %), and 25 (33.8 %) of the 74 patients with measurable disease were classified as grades 0, 1, and 2, respectively ( Table 2) .
Based on the clinical characteristics and the lack of difference in survival rates, grades 0 and 1 were summed as low-grade and grade 2 was defined as high-grade (Table 2) . Those with low-grade PC showed better performance status (PS) than those with high-grade disease, and larger numbers of patients received gastrectomy and second-line chemotherapy compared with those with high-grade disease (p \ 0.001, p \ 0.001, and p = 0.027, respectively). In terms of metastatic LAP, 56.6 % of the patients with low-grade PC and 42.7 % of the patients with high-grade PC had metastatic LAP. This finding may have been related to the more frequent surgical staging and diagnosis of the patients with low-grade disease during surgery. This finding also reflects the discrepancy between surgical staging and preoperative staging in the detection of metastatic LAP. The mean dose of chemotherapy for low-grade PC was higher than that for high-grade PC (p = 0.009) and more patients with low-grade PC than patients with highgrade disease received second line-chemotherapy (80.9 vs. 64.8 %, p = 0.027) ( Table 3) .
Survival of patients with no measurable disease, according to clinical characteristics
The median OS and PFS of patients without measurable disease were 18.6 months (95 % CI 15.9-20.5 months) and 8.27 months (95 % CI 7.3-9.2 months), respectively. On univariate analysis, PS, presence of metastatic LAP, disease status, and carcinomatosis grade had significant effects on PFS and OS. On multivariate analysis, poor PS (HR = 2. Table 4 ).
The clinical characteristics of PC at the time of progression after first-line chemotherapy Among the 137 PC patients without measurable disease, the disease status of 131 could be evaluated at the time of progressive disease after first-line chemotherapy. After progression, 92 (67.2 %) patients still had no measurable disease. The most common cause of progressive disease was increased or newly developed ascites (n = 25, 18.2 %) ( Table 5 ). Of the entire cohort of 211 patients, 149 patients received second-line chemotherapy, 51 patients did not receive second-line chemotherapy, and 11 patients did not progress on first-line chemotherapy. The median OS of the patients who received the second-line chemotherapy was 17.3 months (95 % CI 14.3-20.4 months) and that of the patients who did not receive the second-line chemotherapy was 7.3 months (95 % CI 5.6-9.1 months, p \ 0.001). Among the overall 51 patients who did not receive second line chemotheraphy common reasons for patients not receiving second-line chemotherapy were bowel obstruction 22 (43.1 %), patient's refusal 8 (15.7 %), decreased PS 7 (13.7 %), and an infectious condition 6 (11.7 %).
Survival of patients with PC stratified according to carcinomatosis grade
The median OS of patients without measurable disease was significantly longer than that of patients with measurable disease (18.0 vs. 11.6 months, p = 0.010) (Fig 1) . However, the median OS values in female patients, patients with poor PS, those with Borrmann type IV, and those with recurrent gastric cancer as disease status showed no significant differences between patients with and without measurable disease ( Fig. 1 ; Table 6 ).
The overall median OS and PFS times of patients with grade 0 PC were significantly longer than those of patients with grade 2 PC (p \ 0.001 and p \ 0.001, respectively). However, no differences in PFS or OS were observed between grade 0 and grade 1 PC (Fig. 2a) . Among the patients without measurable disease, the median OS and PFS times of patients with grade 0 PC were significantly longer than the median OS and PFS times of patients with grade 2 PC (p = 0.001 and p = 0.003, respectively). No differences in PFS or OS were observed between grade 0 and grade 1 PC (Fig. 2b) . We summed grades 0 and 1 as the low-grade PC group, owing to the lack of difference in their survival rates, and we classified grade 2 as high-grade PC. All patients were then divided into 4 groups: low-grade PC without measurable disease, high-grade PC without measurable disease, lowgrade PC with measurable disease, and high-grade PC with measurable disease. The median OS time of patients with lowgrade PC without measurable disease was significantly longer than those of the patients in the three other groups (p = 0.001, p = 0.029, and p \ 0.001, respectively) (Fig. 3a) . The median PFS of the low-grade PC group without measurable disease was also significantly longer than those of the patients from the three other groups (p = 0.010, p \ 0.0.001, and p \ 0.001, respectively) (Fig. 3b) . We observed no differences in median OS and PFS between high-grade PC with measurable disease and low-grade PC without measurable disease (p = 0.281 and 0.592, respectively).
Survival of patients with low-grade PC stratified according to gastrectomy status Among the 127 patients with low-grade PC at the time of diagnosis (disease not recurrent), the median OS of patients with low-grade PC with gastrectomy (29.3 months, 95 % CI 17.9-40.7) was longer than that of the patients without gastrectomy (12.5 months, 95 % CI 9.6-15.4, p \ 0.001) (Fig. 4) . Among the patients with low-grade PC, both grade 0 and grade 1 PC patients with gastrectomy showed longer survival than the patients without gastrectomy (p = 0.001 and p = 0.021, respectively) (Fig. 5) . However, for patients with low-grade PC with measurable disease, there was no difference in median OS according to gastrectomy status (p = 0.604). 
Discussion
The majority of PC patients without measurable disease are not eligible for clinical trials; consequently, the outcomes of systemic chemotherapy in this group of patients are not well known. Our study showed that after disease progression following first-line chemotherapy, 67.2 % of patients with evaluable disease still had no measurable lesion at the initiation of second-line chemotherapy. Moreover, patients without measurable disease showed better OS than those with measurable disease. This finding may be attributed to the fact that patients without measurable disease had less LN metastasis and a lower disease burden than those with measurable disease. In terms of tumor burden, 29.2 % of our PC patients without measurable disease received gastrectomy alone or D1/D2 LN dissection. None of these patients had any sign of PC during routine preoperative evaluation. Earlier, Yonemura et al. [5] reported that among patients with PC, those receiving cytoreductive surgery showed better survival. Lee and colleagues [10] reported better survival in their resected metastatic and recurrent disease groups than in the initially metastatic group, and suggested that disease status related to tumor burden and not gastrectomy was an important prognostic Fig. 1 Kaplan-Meier survival analysis for overall survival (OS) rates of gastric cancer patients with peritoneal carcinomatosis (PC) with no measurable disease compared with rates in the patients with measurable disease. CI confidence interval factor for gastric cancer. In the present study, 32.3 % of patients with low-grade PC received a gastrectomy, compared with 0 % of those with high-grade PC. Among the patients with low-grade PC, the patients who received a gastrectomy showed better survival than the patients who did not receive a gastrectomy. We thought that some clinical selection biases for gastrectomy could have been present, such as good PS, less likelihood of metastatic LAP, and fewer peritoneal seeding nodules. Thus, the benefit of palliative gastrectomy should be confirmed by prospective clinical trials. The criteria we used for lowgrade PC were similar to the inclusion criteria for the Reductive Gastrectomy for Advanced Tumor in Two Asian countries (REGATTA) trial-a prospective clinical trial of palliative gastrectomy for gastric cancer with limited PC.
To define the role of palliative gastrectomy for patients with gastric cancer with PC, we should wait for the results of this trial. In terms of tumor burden, several classifications have been applied for PC of gastric cancer. The most commonly used system in Korea and Japan is the Japanese classification of gastric carcinoma (stages P1, P2, and P3) [11] . Other systems, such as the PCI (peritoneal cancer index) or Lyon classification, have also been evaluated for gastric cancer PC [3, 10, 12] . These classification stages were determined after surgical exploration. If patients are to receive systemic chemotherapy alone, surgical exploration will promote morbidity and delay systemic chemotherapy. Our simple classification of PC was determined solely on the basis of clinical factors. PC with the presence of ascites requiring paracentesis, or the presence of bowel wall involvement, such as wall thickening, was classified as high-grade. This patient population has already been established as a poor prognosis group [13] . Grade 0, defined as the presence of peritoneal seeding detected during surgery, is another well-known subgroup classified into P1, P2, and P3 stages, based on surgical exploration. Our data further showed that 43.4 and 32.1 % of patients with grade 0 PC were at the P1 and P2 stages, respectively. The grade 1 group, defined as those with PC detected with preoperative radiologic imaging without clinically significant ascites and bowel wall involvement, has not been classified according to other grading systems for peritoneal caricnomatosis derived from gastric cancer. This group of patients showed better OS than those classified as grade 2, but no differences in OS compared with grade 0 patients, especially in the patients without measurable disease (19.5 vs. 19.6 months, p = 0.639). In addition, this group of patients (i.e., the grade 1 group) had better outcomes with gastrectomy and systemic chemotherapy than with chemotherapy alone. The classifications and clinical characteristics of PC indicate heterogeneity within gastric cancer PC, and treatment strategies should thus be varied according to the PC grade and molecular characteristics.
The response rates of systemic chemotherapy for gastric cancer with PC with measurable disease were reported to be 14-25 % by a number of phase 2 clinical trials [14, 15] . The main reason for the poor response rates of systemic chemotherapy in patients with PC was attributed to the existence of the blood peritoneal barrier, which inhibits drug movement [16] . In earlier studies, the efficacy of cytoreductive surgery and intraperitoneal (IP) chemotherapy was evaluated in patients with PC [3, 6] . The results for gastric cancer were the worst among those for gastrointestinal cancers with PC [3] . In patients with PC who had cytoreductive surgery and IP chemotherapy, Glehen et al. [3] reported that the PCI, completeness of surgery, and LN metastasis were significant prognostic factors for OS. LN metastasis was shown in 117 of their 125 gastric cancer patients with PC [3] . In our present study, 52.1 % of patients had metastatic LAP before systemic chemotherapy was begun. In view of the limitations of the effects of IP chemotherapy for PC with LN metastasis and the frequent LN metastasis in gastric cancer with PC, other treatment strategies should be employed for this disease [5, 6] . In terms of newer treatment strategies, it has been shown that angiogenesis is important for the development of gastric cancer PC, and the inhibition of angiogenesis is reported to be effective for the management of PC [17] [18] [19] . Yagi et al. [20] reported that, in a PC model for gastric cancer, systemic administration of a monoclonal antibody against vascular endothelial growth factor (VEGF) was effective in reducing ascites and inhibiting tumor growth. In addition, systemic administration of the VEGF antibody was more effective than intraperitoneal administration [20] . Subgroup analysis of a phase 3 clinical trial of bevacizumab, a monoclonal antibody against VEGF, revealed a greater survival benefit in gastric cancer patients without measurable disease than in those with measurable disease [7] . We hypothesized that a considerable proportion of these patients had PC, and that bevacizumab had led to the normalization of abnormal tumor blood vessels and increased the delivery of systemic chemotherapeutic drugs. Another approach involved concurrent IP and systemic chemotherapy and cytoreductive surgery. Yonemura et al. [21, 22] and Fujiwara et al. [21, 22] reported that a combined approach with both IP and systemic chemotherapy and cytoreductive surgery increased the efficacy of treatment outcomes in gastric cancer with PC.
Our study had several limitations inherent to retrospective analyses. In terms of treatment characteristics in particular, regimens of chemotherapy and surgery types were not homogeneous across patients or groups. However, we collected information on the natural treatment history of gastric cancer patients with PC without measurable disease, and to our knowledge, this is the first reported evaluation of the clinical characteristics and outcomes of systemic chemotherapy in patients with gastric cancer with PC.
According to the results of our study, we considered that aggressive multimodal treatment, including palliative gastrectomy and/or D1/D2 LN dissection followed by systemic intravenous chemotherapy, was associated with better outcomes in patients with low-grade PC without measurable disease on the preoperative CT scan (these patients were less likely to have metastatic LAP, clinically significant ascites, or bowel involvement), especially when the patients had a good PS. Compared with these patients with low-grade PC, patients with high-grade PC had poor outcomes with the above current practices; thus, it would be better to treat such patients with newer systemic anticancer agents such as anti-angiogenic agents. However, as these different treatment strategies are based not only on clinical characteristics but also on specific molecular characteristics, vigorous study of the molecular characteristics of gastric cancer PC should be performed. In addition, the efficacy of palliative gastrectomy, including cytoreductive surgery and systemic chemotherapy, in patients with low-grade PC without measurable disease should be evaluated separately in prospective trials.
In conclusion, we showed here the clinical characteristics of PC arising from gastric cancer in relation to the clinical grade and outcomes of systemic chemotherapy, especially in patients without measurable disease. And, based on our study, we also suggest that clinical trials in patients with PC arising from gastric cancer should be stratified according to PC grade.
